Clopidogrel Response Variability
Authors:
Open Access
- 20 November 2015
- journal article
- research article
- Published by SAGE Publications in Journal of Pharmacy Practice
- Vol. 29 (1) , 26-34
Abstract
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is standard therapy following acute coronary syndrome and percutaneous coronary intervention. Despite the use of potent antiplatelet agents, vascular events continue to occur. Lack of response to clopidogrel therapy has been widely investigated using various methods of platelet function testing. These studies have consistently found an association between poor clopidogrel response and an increased risk of vascular events. Strategies to overcome this problem include higher clopidogrel doses or the use of an alternative P2Y12 agent. To date, the majority of studies investigating tailored antiplatelet therapy have failed to show any reduction in clinical events likely due to the low-risk population studied. Despite this lack of benefit from altering therapy, platelet function testing may be done in certain patient populations. Patients at high risk of deleterious outcomes from stent thrombosis may be an appropriate patient population for platelet function testing to ensure adequate response to therapy. In addition, emerging data suggests a potential role for platelet function testing to assess for bleeding risk. The purpose of this article is to review the key studies demonstrating response variability to clopidogrel therapy, strategies to overcome variability, and practical considerations for the clinician.Keywords
This publication has 53 references indexed in Scilit:
- 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive SummaryCirculation, 2014
- Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and SafetyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
- 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive SummaryJACC, 2013
- Emerging Antiplatelet Therapy for Coronary Artery Disease and Acute Coronary SyndromePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive SummaryCirculation, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel TherapyClinical Pharmacology & Therapeutics, 2011
- Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y12 InhibitorPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009
- Aspirin ResistanceProgress in Cardiovascular Diseases, 2009
- Platelet Function Monitoring in Patients With Coronary Artery DiseaseJACC, 2007
- ClopidogrelDrugs, 2007